JAMIE E MCKENZIE

Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology TAMPA, FL NPI 1104953546

General Payments — all program years on this page

$21,945.88

Category: General Payments
Program years: PY2018–2024
Record count: 76
As of (CMS publication): 2026-01-23

Latest program year (PY2024): $17,865.39 across 43 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated

The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of payment	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$12,540.00	4
Consulting Fee	$2,627.50	2
Food and Beverage	$1,289.57	24
Long term medical supply or device loan	$1,096.70	11
Travel and Lodging	$311.62	2

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entity	Amount	Records
Acerta Pharma LLC	$13,487.91	14
PFIZER INC.	$1,450.03	2
Stemline Therapeutics Inc.	$1,267.33	2
NOVARTIS PHARMACEUTICALS CORPORATION	$1,149.19	16
Daiichi Sankyo Inc.	$119.03	1
Lilly USA, LLC	$101.96	1
Incyte Corporation	$100.00	1
TerSera Therapeutics LLC	$65.04	1
Genentech, Inc.	$38.48	1
Genentech USA, Inc.	$33.27	2
PUMA BIOTECHNOLOGY, INC.	$32.80	1
Tempus AI, Inc	$20.35	1

By program year

Program year	Amount	Records
2018	$128.00	2
2019	$94.16	3
2020	$36.77	2
2021	$26.64	2
2022	$479.43	8
2023	$3,315.49	16
2024	$17,865.39	43

Records — PY2024 (43)

Record ID	Paying entity	Amount	Date	Nature of payment	Dispute status	Published	Source
1087115544	Novartis Pharmaceuticals Corporation	$16.35	02/09/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1087115552	Novartis Pharmaceuticals Corporation	$10.94	03/27/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1087115560	Novartis Pharmaceuticals Corporation	$9.95	05/01/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1087115568	Novartis Pharmaceuticals Corporation	$9.04	09/06/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1087115570	Novartis Pharmaceuticals Corporation	$99.70	08/23/2024	Long term medical supply or device loan	Undisputed	01/23/2026	View at CMS
1087115572	Novartis Pharmaceuticals Corporation	$99.70	09/27/2024	Long term medical supply or device loan	Undisputed	01/23/2026	View at CMS
1087115574	Novartis Pharmaceuticals Corporation	$99.70	02/16/2024	Long term medical supply or device loan	Undisputed	01/23/2026	View at CMS
1087115576	Novartis Pharmaceuticals Corporation	$99.70	03/15/2024	Long term medical supply or device loan	Undisputed	01/23/2026	View at CMS
1087115578	Novartis Pharmaceuticals Corporation	$99.70	04/18/2024	Long term medical supply or device loan	Undisputed	01/23/2026	View at CMS
1087115580	Novartis Pharmaceuticals Corporation	$99.70	05/16/2024	Long term medical supply or device loan	Undisputed	01/23/2026	View at CMS
1087115582	Novartis Pharmaceuticals Corporation	$99.70	06/13/2024	Long term medical supply or device loan	Undisputed	01/23/2026	View at CMS
1087115584	Novartis Pharmaceuticals Corporation	$99.70	07/15/2024	Long term medical supply or device loan	Undisputed	01/23/2026	View at CMS
1087115588	Novartis Pharmaceuticals Corporation	$6.21	09/20/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1087115590	Novartis Pharmaceuticals Corporation	$99.70	11/14/2024	Long term medical supply or device loan	Undisputed	01/23/2026	View at CMS
1087115592	Novartis Pharmaceuticals Corporation	$99.70	10/17/2024	Long term medical supply or device loan	Undisputed	01/23/2026	View at CMS
1087115602	Novartis Pharmaceuticals Corporation	$99.70	12/10/2024	Long term medical supply or device loan	Undisputed	01/23/2026	View at CMS
1089455248	Daiichi Sankyo Inc.	$119.03	12/12/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1104279335	AstraZeneca Pharmaceuticals LP	$45.02	03/08/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1104355626	AstraZeneca Pharmaceuticals LP	$116.28	08/26/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1104376613	AstraZeneca Pharmaceuticals LP	$29.74	08/26/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1104476996	AstraZeneca Pharmaceuticals LP	$4,450.00	01/26/2024	Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	Undisputed	01/23/2026	View at CMS
1104511986	AstraZeneca Pharmaceuticals LP	$124.98	01/18/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1104514374	AstraZeneca Pharmaceuticals LP	$120.87	04/10/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1104631336	AstraZeneca Pharmaceuticals LP	$4,450.00	04/29/2024	Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	Undisputed	01/23/2026	View at CMS
1104636005	AstraZeneca Pharmaceuticals LP	$15.48	01/18/2024	Travel and Lodging	Undisputed	01/23/2026	View at CMS
1105457208	AstraZeneca Pharmaceuticals LP	$1,387.50	12/20/2024	Consulting Fee	Undisputed	01/23/2026	View at CMS
1105497519	AstraZeneca Pharmaceuticals LP	$22.82	01/20/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1105511919	AstraZeneca Pharmaceuticals LP	$296.14	04/10/2024	Travel and Lodging	Undisputed	01/23/2026	View at CMS
1105628478	AstraZeneca Pharmaceuticals LP	$107.95	03/07/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1105711388	AstraZeneca Pharmaceuticals LP	$2,200.00	05/08/2024	Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	Undisputed	01/23/2026	View at CMS
1105900810	AstraZeneca Pharmaceuticals LP	$121.13	03/28/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1131709929	PFIZER INC.	$10.03	01/20/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1132013692	PFIZER INC.	$1,440.00	08/15/2024	Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	Undisputed	01/23/2026	View at CMS
1133026354	Genentech, Inc.	$38.48	12/13/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1133026358	Genentech USA, Inc.	$15.29	11/07/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1133026362	Genentech USA, Inc.	$17.98	02/22/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1135048452	Lilly USA, LLC	$101.96	05/16/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1141226078	Incyte Corporation	$100.00	07/10/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1142960617	Stemline Therapeutics Inc.	$27.33	01/05/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1142960619	Stemline Therapeutics Inc.	$1,240.00	12/05/2024	Consulting Fee	Undisputed	01/23/2026	View at CMS
1144715613	TerSera Therapeutics LLC	$65.04	11/05/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1147708248	Puma Biotechnology, Inc.	$32.80	12/12/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS
1150169668	Tempus AI, Inc	$20.35	10/14/2024	Food and Beverage	Undisputed	01/23/2026	View at CMS

Provenance & corrections

Dataset: CMS Open Payments — General Payments
Source: CMS Open Payments dataset (bulk file)
Publisher of source data: Centers for Medicare & Medicaid Services
Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.